Agile Therapeutics Inc. (NASDAQ:AGRX) – Stock analysts at FBR & Co boosted their FY2016 earnings estimates for shares of Agile Therapeutics in a report issued on Monday. FBR & Co analyst E. White now anticipates that the firm will post earnings per share of ($1.11) for the year, up from their prior forecast of ($1.22). FBR & Co currently has a “Buy” rating and a $16.00 price target on the stock. FBR & Co also issued estimates for Agile Therapeutics’ Q4 2016 earnings at ($0.28) EPS, FY2017 earnings at ($1.34) EPS and FY2018 earnings at $1.17 EPS.

Separately, Noble Financial restated a “buy” rating and set a $15.00 target price on shares of Agile Therapeutics in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $14.20.

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics (NASDAQ:AGRX) opened at 6.64 on Thursday. Agile Therapeutics has a one year low of $5.32 and a one year high of $10.41. The stock’s market capitalization is $190.91 million. The stock has a 50 day moving average price of $7.29 and a 200-day moving average price of $7.13.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Monday, November 7th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.08.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rice Hall James & Associates LLC boosted its position in Agile Therapeutics by 1.2% in the third quarter. Rice Hall James & Associates LLC now owns 25,631 shares of the specialty pharmaceutical company’s stock worth $179,000 after buying an additional 314 shares in the last quarter. Hamilton Lane Advisors LLC acquired a new position in Agile Therapeutics during the third quarter worth approximately $387,000. Bridgeway Capital Management Inc. boosted its position in Agile Therapeutics by 66.8% in the second quarter. Bridgeway Capital Management Inc. now owns 112,334 shares of the specialty pharmaceutical company’s stock worth $855,000 after buying an additional 45,000 shares in the last quarter. State Street Corp boosted its position in Agile Therapeutics by 34.2% in the second quarter. State Street Corp now owns 133,438 shares of the specialty pharmaceutical company’s stock worth $1,015,000 after buying an additional 34,033 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its position in Agile Therapeutics by 193.9% in the second quarter. Perceptive Advisors LLC now owns 514,288 shares of the specialty pharmaceutical company’s stock worth $3,914,000 after buying an additional 339,288 shares in the last quarter. Hedge funds and other institutional investors own 84.33% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

5 Day Chart for NASDAQ:AGRX

Receive News & Stock Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related stocks with our FREE daily email newsletter.